John V. Oyler is a biotechnology executive and entrepreneur with a longstanding focus on oncology drug development and translational science. He is the Co-Founder, Chairman, and Chief Executive Officer of BeOne Medicines, a global biopharmaceutical company specializing in oncology drug discovery, development, and commercialization. Oyler co-founded the company in 2010 with biochemist Xiaodong Wang and has since led its expansion into a multinational oncology enterprise with operations across more than 45 countries and over 11,000 employees.
Across his career, Oyler has consistently worked at the intersection of science, strategy, and execution, with a particular emphasis on building organizations capable of translating complex biology into clinically meaningful cancer therapies, serving as President and CEO of BioDuro, and earlier in executive positions at Genta and Telephia. Oyler’s entrepreneurial contributions to biopharmaceutical innovation have been recognized in industry lists such as The Medicine Maker 2025 Power List in the biopharmaceutical category and as a 2025 Entrepreneur of the Year National Health Award recipient.
The 100 Most Influential People in Oncology in 2025 recognizes the changemakers in cancer care who have helped shape current practice in oncology and continue to drive innovation and research towards better outcomes, advocacy, philanthropy, leadership and education. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential People in Oncology in 2025 and stay tuned for the results of special category nominations to be announced.
